nature.com
Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC) - Nature Medicine
An updated pooled analysis of 3-year and 5-year survival and other outcome data of 1,038 patients with melanoma treated with neoadjuvant immune checkpoint inhibitors (ICIs), BRAF and MEK inhibitors (B...